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Background: This study assessed the relationship between asthma burden and
asthma severity in France, Italy, and Spain.
Methods: Adult asthmatics, 18–55 years of age, completed a questionnaire while
visiting a respiratory physician in 1998 and 1999. Asthma severity was categorized by
physicians as intermittent, mild persistent, moderate persistent, or severe
persistent according to Global Initiative for Asthma (GINA) guidelines.
Results: Totals of 282 patients in France, 500 in Italy, and 296 in Spain entered the
study. There were few differences between the three countries in the asthma
symptom burden. Most patients with persistent asthma had used inhaled
corticosteroids in the previous 14 days. Unexpectedly, 35% (Italy) to 83% (Spain) of
patients with intermittent asthma also had used inhaled corticosteroids. In Spain,
visits to the emergency department were more frequent (OR 7.0, 95% CI 4.9–10.0
with Italy as reference) and the costs of emergency care in all asthma severity
categories were up to 10 times higher than in Italy and France. The frequency of
hospitalizations did not differ systematically between the three countries.
Conclusions: Inadequate control of asthma symptoms among patients with severe
persistent asthma could not be entirely explained by under-prescribing of asthma
medications. The use of inhaled corticosteroids by patients with intermittent asthma
might reflect misclassification of asthma severity, possibly due to difficulty in
interpreting the GINA guidelines. The relatively high cost of emergency care in SpainElsevier Ltd. All rights reserved.
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Asthma resource use by severity in France, Italy and Spain 141does not appear to be related to greater asthma severity or poorer symptom control,
but may be a feature of the Spanish health care system.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The treatment recommendations for asthma in
international guidelines depend on the underlying
severity of the disease. In principle, asthma
severity is determined most accurately by the
patient’s clinical condition in the absence of
therapy. Appropriate therapy minimizes the symp-
tom burden, so that the presence of residual
symptoms and exacerbations in treated patients
reflects lack of control: this defines the difference
between severity and control.1 The determination
of underlying severity is thus important, not only
in determining treatment, but also in assessing
the effectiveness of the treatment and the
societal costs of inadequate control, measured in
terms of the symptom burden and the costs of
emergency care.
Asthma severity has frequently been determined
on the basis of symptoms in populations already
being treated. But treatment confounds the assess-
ment severity and control.2–5 Furthermore, most
studies of the asthma burden apply to a specific
country and cannot be extrapolated to other
countries, because of variations in health care
systems, provider behavior, and patient character-
istics. Here we report a study that compares the
relationship between severity and the asthma
burden in three major European countries. Severity
was determined by taking into account the
three dimensions of symptoms, lung function, and
medication use, in accordance with the Global
Initiative for Asthma (GINA) guidelines,6–8 as a
practical means of categorizing patients in
populations already receiving treatment.9 The
objectives were, first, to evaluate asthma-related
resource use in a selection of European countries
according to asthma severity and, second, to
compare variations in asthma-related resource
use between the countries, using the same criteria
for severity.Methods
Study design and procedures
This study was a survey of consecutive adults with
asthma, conducted during regularly scheduledvisits to respiratory clinics (nine in France,
16 in Italy, and 52 in Spain) during 1998 and
1999. The participating physicians in France
and Italy were allergists, pulmonologists, or inter-
nists experienced in asthma care and the clinics
were a convenience sample in each country. In
Spain, the participating physicians were family and
community physicians (Medicina de Familia y
Communitaria) providing continuous care for asth-
ma and other respiratory diseases. Specialist
centers, rather than general practices, were
chosen to ensure a patient sample that included
all degrees of asthma severity. The methods did not
differ between countries and have been previously
described in detail for the Italian arm of the
study.10
In brief, patients were eligible if they were
between 18 and 55 years of age and had at least a
1-year history of asthma. During the course of a
routine office visit, patients recorded socio-demo-
graphic information, asthma symptoms in the
previous 14 days, asthma medication use during
past 14 days, physician visits during past 6 months,
and hospitalization and emergency department
visits during past year, using a self-administered
questionnaire. Productivity loss in the past year
was recorded as paid workday loss per month and
decreased effectiveness at work. Physicians cate-
gorized the severity of the patient’s asthma as
intermittent, mild persistent, moderate persistent,
or severe persistent, according to the 1995 GINA
classification system,11 based on a combination of
symptom and FEV1 criteria and the GINA recom-
mendations for medication appropriate at each
level of severity.7 Asthma severity levels were
determined for the past 14 days. For the cost
analysis, units of resource consumption obtained
from the questionnaires were extrapolated to a
1-year period without adjustment. Unit drug costs
were taken from the official drug wholesale price
lists in the respective countries, and costs of
ambulatory visits, tests, and hospital admissions
were based on the official tariffs of the respective
national health services. Indirect costs were esti-
mated as the asthma-related productivity loss
multiplied by the average wage, obtained from
national statistical institutes in each country. Costs
were calculated in local currencies and converted
to 1999 Euros. The total cost of asthma was the sum
of the direct medical cost and the indirect cost.
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The chi-square test (homogeneity of distribution)
was used to assess associations between asthma
severity and categorical variables. General linear
models were used to assess the relationship
between asthma severity and continuous variables.
The non-parametric Kruskal–Wallis test was applied
when the variable had a skewed distribution.
Multivariable logistic regression models were con-
structed to determine the associations between
asthma severity and asthma-related hospital ad-
missions and emergency department visits. A two-
tailed P valueo0.05 was considered significant and
all analyses were carried out using SAS software
package (version 8.2).Results
Patient population
One thousand and seventy-eight patients were
included in the analysis: 282 in France, 500 in Italy,
and 296 in Spain. Italy and Spain had similar
distributions of asthma severity, with 35–44% of
patients classified as having intermittent asthma
and 4–8% classified as having severe persistent
asthma (Table 1). Conversely, only 4% of patients in
France had intermittent asthma, while 28% had
severe persistent asthma. Female patients predo-
minated, but there was no relationship between
sex and asthma severity. The mean patient age
increased statistically significantly with asthma
severity in all three countries.Table 1 Patient characteristics by asthma severity and
Asthma severity
Intermittent Mild persistent M
Patient number (%)
France (N ¼ 282) 12 (4%) 88 (31%) 1
Italy (N ¼ 500) 174 (35%) 134 (27%) 1
Spain (N ¼ 296) 131 (44%) 85 (29%) 6
Female (%)
France 54.6 62.5 5
Italy 56.3 53.7 5
Spain 67.7 76.5 6
Age, mean years (SD)
France 37.2 (9.9) 35.0 (11.8) 3
Italy 34.2 (9.8) 36.0 (10.5) 3
Spain 35.0 (11.3) 39.2 (11.5) 3Asthma symptom burden
All categories of asthma symptoms reported by
patients increased with asthma severity (Table 2).
There was no striking difference between the three
countries in the asthma symptom burden in each
severity category, although the burden was higher
in Italy in some instances—nights woken up in
patients with severe persistent asthma; and impact
of asthma exacerbations in patients with moderate
and severe persistent asthma.
Asthma medications
Most but not all patients with persistent asthma
had used inhaled corticosteroids in the 14 days
prior to completing the questionnaire (Table 3).
Unexpectedly, 35–83% of patients with intermittent
asthma had also used inhaled corticosteroids.
There was less use of inhaled corticosteroids in
Italy than in the other two countries.
Asthma-related medical service use
The use of all categories of medical services tended
to increase with asthma severity (Table 4). Italy and
Spain were similar in terms of the numbers of
patient-reported GP visits, which for patients in the
intermittent, mild-, and moderate persistent cate-
gories were approximately 2–4 times more frequent
than in France. In other categories of medical
service use, however, Spain was distinct from the
other two countries: in Spain, visits to specialist
physicians were less frequent and visits to the
emergency department were more frequent than incountry.
P value
oderate persistent Severe persistent
02 (36%) 80 (28%) —
53 (31%) 39 (8%) —
9 (23%) 11 (4%) —
9.8 57.5 NS
6.9 74.4 NS
9.6 90.9 NS
9.3 (10.5) 41.0 (10.7) 0.0034
8.5 (10.8) 42.0 (11.6) o0.0001
9.1 (11.4) 47.5 (9.6) 0.0005
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Table 2 Patient-reported symptoms during the previous 14 days by asthma severity and country.
Asthma severity P value
Intermittent Mild persistent Moderate persistent Severe persistent
Mean days with symptoms (SD)
France 1.9 (3.9) 3.2 (4.8) 4.2 (4.9) 8.8 (5.8) o0.0001
Italy 1.1 (1.9) 4.3 (4.4) 6.4 (5.0) 9.3 (5.3) o0.0001
Spain 1.5 (3.0) 3.4 (4.2) 7.5 (5.6) 8.4 (6.1) o0.0001
Mean nights woke up (SD)
France 0.9 (2.9) 1.0 (2.8) 1.2 (2.4) 4.4 (5.5) o0.0001
Italy 0.2 (0.7) 1.3 (2.1) 3.1 (4.0) 7.2 (5.8) o0.0001
Spain 0.5 (1.9) 0.7 (1.5) 2.8 (4.1) 3.5 (4.7) o0.0001
Moderately or severely limited in normal daily activities (%)
France 0 8.0 19.6 57.5 o0.0001
Italy 0 1.5 26.8 59.0 o0.0001
Spain 1.5 3.5 20.3 54.6 o0.0001
Moderate or major impact of asthma exacerbationsy (%)
France 0 8.0 11.8 38.8 o0.0001
Italy 0 3.7 26.8 66.7 o0.0001
Spain 2.3 3.5 11.6 45.5 o0.0001
Limited most or all of the time.
yImpact on sleep and activities most or all of the time.
Table 3 Patient-reported medication use during the past 14 days by asthma severity and country.
Asthma severity P value
Intermittent Mild persistent Moderate persistent Severe persistent
Short-acting beta-agonists (%)
France 75.0 65.9 71.6 82.5 NS
Italy 35.1 81.5 64.1 79.5 o0.0001
Spain 61.1 81.2 78.3 81.8 0.0045
Inhaled corticosteroids (%)
France 83.3 80.7 93.1 95.0 0.0087
Italy 35.1 66.4 75.2 64.1 o0.0001
Spain 71.8 88.2 89.9 100.0 0.0008
Long-acting beta-agonists (%)
France 58.3 44.3 65.7 77.5 0.0001
Italy 25.3 53.0 64.7 51.3 o0.0001
Spain 28.2 31.8 55.1 72.7 0.0001
Oral corticosteroids (%)
France 0 8.0 7.8 42.5 o0.0001
Italy 4.0 5.2 15.7 33.3 o0.0001
Spain 3.8 1.2 5.8 27.3 0.001
Asthma resource use by severity in France, Italy and Spain 143Italy and France. Hospitalizations did not differ
systematically across these three countries, but
instead correlated with asthma severity. In all
countries, the difference between severe persis-
tent and other severity categories in hospitalization
rates was dramatic.Predictors of emergency care
In multivariable logistic models, patients in Spain
were more likely to visit the emergency depart-
ment than patients in Italy (odds ratio [OR] 7.0, 95%
confidence interval [CI] 4.9–10.0), while patients in
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Table 4 Patient reported asthma-related medical service use during the past year by severity and country.
Asthma severity P value
Intermittent Mild persistent Moderate persistent Severe persistent
GP visits, mean number (SD)
France 1.3 (2.7) 1.8 (3.6) 2.1 (2.9) 7.7 (10.6) o0.0001
Italy 3.1 (5.7) 4.8 (8.6) 6.2 (12.6) 8.6 (12.0) 0.0019
Spain 4.2 (4.3) 6.4 (5.6) 7.8 (6.7) 10.0 (4.9) o0.0001
Specialist visits, mean number (SD)
France 3.2 (1.6) 3.2 (2.4) 4.1 (4.6) 6.9 (6.3) o0.0001
Italy 3.5 (3.7) 4.5 (5.5) 4.3 (6.4) 4.7 (4.5) NS
Spain 0.9 (1.6) 1.1 (2.2) 1.4 (2.3) 2.5 (5.9) NS
Emergency department visits (%)
France 8.3 13.6 6.9 25.0 0.0057
Italy 6.3 14.9 21.6 38.5 o0.0001
Spain 46.6 48.2 65.2 72.7 0.0329
Hospitalizations (%)
France 8.3 8.0 9.8 38.8 o0.0001
Italy 3.5 6.7 8.5 33.3 o0.0001
Spain 5.3 5.9 7.3 27.3 0.0483
E. Van Ganse et al.144France were least likely to visit the emergency
department (OR 0.6, 95% CI 0.4–0.9, with Italy as
reference). The likelihood of an emergency depart-
ment visit also increased with asthma severity.
Patients with mild- (OR 1.6, 95% CI 1.1–2.5),
moderate- (OR 2.3, 95% CI 1.5–3.6), or severe-
persistent asthma (OR 5.6, 95% CI 3.2–9.9) were
more likely to visit the emergency department than
patients with intermittent asthma.
Multivariable logistic models revealed no signifi-
cant difference between the countries in the
likelihood of a hospital visit over a 1-year period,
while patients with severe asthma were more likely
to be hospitalized than patients with intermittent
disease regardless of the country (OR 10.4, 95% CI
5.2–21.9).Cost of asthma
The per-patient costs of asthma increased with
increasing asthma severity (Table 5). Drug costs
were lower in Italy than in the other two countries.
The costs of emergency care were highest in Spain
in all severity categories: 7 times higher than in
France in the moderate persistent category and
almost 10 times higher than in Italy in the severe
persistent category. Direct costs exceeded indirect
costs in France and Spain, but in Italy direct and
indirect costs were comparable.Discussion
This study applied a uniform methodology to the
determination of asthma severity in 1078 adults
attending clinics in France, Italy, and Spain. In all
three countries the level of symptom control was
poor among patients in the moderate and severe
persistent asthma categories. Poor asthma control
has been reported in population-based surveys of
European countries, though the relationship with
severity has not been previously clarified.2,4,12–14
Poor asthma symptom control may be due in part to
under-use of asthma controller medications. Not all
patients with persistent asthma were using inhaled
anti-inflammatory drugs, particularly in Italy,
where inhaled corticosteroid use was lower, while
the symptom burden was by some measures higher,
than in France or Spain.
It seems unlikely, however, that the poor symp-
tom control can be entirely explained by under-
prescribing of asthma medications. Currently avail-
able medications do not achieve complete control
of asthma in all patients even in the context of
clinical trials.15 Furthermore, virtually all patients
(X99%) with persistent asthma in this study
reported the use of one or more asthma medica-
tions in the previous 14 days. Most patients (X90%)
with moderate or severe persistent asthma in
France and Spain reported use of inhaled corticos-
teroids. The ratio of inhaled corticosteroid to short-
acting beta-agonist use was approximately unity in
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Table 5 Per-patient cost of asthma in euros by asthma severity and country.
Asthma severity P value
Intermittent Mild persistent Moderate persistent Severe persistent
ED and hospitalization
France 180 (620) 220 (800) 250 (800) 290 (260) o0.0001
Italy 66 (340) 300 (1900) 240 (1100) 890 (1400) 0.002
Spain 210 (450) 340 (690) 1800 (11,000) 8600 (27,000) 0.0019
Physician visits
France 96 (56) 110 (99) 130 (120) 290 (260) o0.0001
Italy 110 (110) 150 (180) 170 (220) 210 (170) 0.0031
Spain 110 (130) 150 (190) 180 (200) 250 (320) 0.0081
Asthma-related drugs
France 560 (460) 490 (700) 810 (470) 1400 (900) o0.0001
Italy 120 (630) 93 (260) 350 (1200) 400 (1300) 0.0166
Spain 330 (850) 540 (1100) 520 (980) 1300 (1800) 0.0187
Direct medical cost
France 840 (1000) 820 (1100) 1200 (1000) 3300 (3000) o0.0001
Italy 300 (730) 550 (2000) 760 (1700) 1500 (2200) 0.0002
Spain 650 (1100) 1000 (1600) 2500 (11,000) 10,000 (27,000) 0.0004
Indirect cost
France 0 95 (370) 60 (260) 880 (2700) 0.0009
Italy 420 (1300) 500 (1300) 780 (2100) 1800 (3900) 0.0003
Spain 180 (900) 180 (700) 250 (790) 16 (54) NS
Total cost
France 840 (1000) 910 (1300) 1300 (1100) 4100 (4300) o0.0001
Italy 720 (1500) 1000 (2500) 1500 (2700) 3300 (4900) 0.0001
Spain 830 (1500) 1200 (1900) 2700 (11,000) 10,000 (27,000) 0.0006
Values represent mean (SD) asthma-related cost, given to two significant figures.
Asthma resource use by severity in France, Italy and Spain 145all three countries. This contrasts with previous
reports from population-based studies in France,
Italy, and Spain, where the ratio of inhaled
corticosteroids to quick-relief medications was
o0.35.2,16
Neither poor symptom control nor under-use of
asthma drugs appear to explain the extremely high
rate of emergency department visits in Spain
(between 47% and 73% of patients, depending on
severity). The asthma symptom burden in Spain was
comparable to that in France and Italy. Similarly,
the use of inhaled corticosteroids and short-acting
beta-agonists was as great or greater in Spain than
in France or Italy. A high rate of emergency care
visits in Spain was noted in the population-based
AIRE study and in the European Community Re-
spiratory Health Survey.3,16 In the AIRE survey, 22%
of adults with asthma visited the emergency
department in the previous year in Spain, com-
pared with 5% in France and 11% in Italy.16 This
difference could not be attributed to a difference
in asthma medication compliance.3 A concomi-tantly low frequency of specialist visits in Spain
suggests that the high frequency of emergency
department visits is a feature of the health care
system: patients in Spain may use the emergency
department for routine visits and not just for
emergency care. A study of hospital emergency
services use in Barcelona indicated that only 38% of
cases were actual emergencies.17 The factors
invoked to explain this were related to demand
(an ageing population, a ‘hospital-centric’ culture,
health education) and supply (lack of accessible
primary care facilities, greater accessibility of
hospitals), although these factors do not entirely
explain the phenomenon.17
As the classification of asthma severity according
to GINA criteria has not been validated against a
‘gold standard’ (e.g., determination of severity
based on symptoms in the absence of drug treat-
ment), the categorizations may have been inaccu-
rate. Differences between countries in physician
specialty might also have contributed to differ-
ences in severity classification. The investigators in
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having intermittent asthma) were respiratory spe-
cialists, whereas those in Spain (where 44% of
patients were in the intermittent category) were
family and community physicians. The surprising
finding, that from 35.1% (Italy) to 83.3% (France) of
patients with intermittent asthma had used inhaled
corticosteroids in the previous 14 days, might be
explained by misclassification of asthma severity.
That is, it is possible that the control of asthma
symptoms resulting from the use of inhaled
corticosteroids was confounded with the absence
of persistent asthma. This might indicate the
difficulty in applying GINA guidelines to determin-
ing asthma severity in clinical practice. The limited
data available indicate that the inter-rater relia-
bility of severity classification using the guidelines
is poor, though treatment recommendations are
consistent with physicians’ severity classifica-
tions.18 The use of inhaled corticosteroids by
patients in the intermittent category might never-
theless reflect mis-prescribing of asthma medica-
tions. The asthma medications that patients
reported taking in the previous 14 days had been
prescribed in an earlier visit to a GP or other
physician, who then referred the patient to the
investigating physician. That is, the referring
physician rather than the investigating respiratory
physician may have misdiagnosed the severity of
the patients’ asthma. This argument is applicable
to Italy and Spain, but less so to France, where
relatively few patients (4%) were in the intermit-
tent asthma category. In France it is more likely
that, as allowed in the GINA guidelines, patients
with intermittent asthma were prescribed a short
course of inhaled corticosteroids to treat a tran-
sient episode of severe symptom exacerbation.6
Limitations in the study design affect the inter-
pretability of the results. We limited the study to
patients seen by respiratory physicians. Because of
this and other patient selection criteria, the
patients were not nationally representative sam-
ples and our observations might not be general-
izable to all people with asthma in the three
countries studied. A study carried out in Italy in
1998–2000 indicated that only 57.4% of young
adults with asthma had been seen by a doctor in
the previous 12 months, but that almost two-thirds
of those who (62.5%) had been seen by a specialist.4
The recall periods specified in the study question-
naire were chosen to maximize the accuracy of
self-reported data for events of differing frequen-
cies: a 14-day recall period for common events
(asthma symptoms and medication use) and 6- and
12-month recall periods for less frequent events
(emergency care). While a short recall period mightaccurately reflect the actual events,19 there is
uncertainty in extrapolating to longer time frames.Conclusions
A GINA-based severity classification system that
took into account symptoms, lung function, and
medication use, was applied in an attempt to
distinguish between asthma severity and control.
Incomplete control of asthma, particularly among
patients with moderate and severe persistent
asthma, occurred at comparable rates in France,
Italy, and Spain, and could only partly be explained
by under-prescription of asthma medications. Simi-
lar rates of hospitalization in the three countries
suggest relative homogeneity in admission policies.
The reasons for a high frequency of emergency
department visits in Spain require further study.Acknowledgments
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